LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Per the terms, the pharma giant will acquire all outstanding shares (including American Depositary Shares) of CNTA for $38 per share in cash, aggregating to about $6.3 billion. In addition, Centessa's shareholders will receive one non-tradable contingent value right (CVR) per share. This CVR entitles holders to an additional cash payment of up to $9 per share, contingent on achieving FDA approvals of either of its two pipeline drugs (cleminorexton and ORX142) across narcolepsy type II and idiopathic hypersomnia (IH) indications over the next few years. Including the CVR, the total potential deal value reaches approximately $7.8 billion. Post this acquisition, Lilly will add Centessa's pipeline of orexin receptor 2 (OX2R) agonists for treating people with sleep-wake disorders. This includes the lead drug, cleminorexton (formerly ORX750), which is being evaluated in a mid-stage study for two types of narcolepsy (type I and II) and IH. Last year, CNTA reported initial results from th
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host diseaseGlobeNewswire
- Sanofi Oncology And Rare Disease Updates Spark Fresh Valuation Interest [Yahoo! Finance]Yahoo! Finance
- Sanofi eczema drug weighed down by mixed results, safety concerns [Yahoo! Finance]Yahoo! Finance
- Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 3/31/26 - Form 6-K
- 3/24/26 - Form 6-K
- 3/10/26 - Form 6-K
- SNY's page on the SEC website